The stock of Delcath Systems, Inc. (NASDAQ:DCTH) is a huge mover today! About 2.39 million shares traded hands or 4670.08% up from the average. Delcath Systems, Inc. (NASDAQ:DCTH) has declined 63.36% since April 4, 2016 and is downtrending. It has underperformed by 64.45% the S&P500.
The move comes after 7 months positive chart setup for the $3.66M company. It was reported on Nov, 4 by Barchart.com. We have $3.81 PT which if reached, will make NASDAQ:DCTH worth $3.11 million more.
Analysts await Delcath Systems, Inc. (NASDAQ:DCTH) to report earnings on November, 8.
According to Zacks Investment Research, “Delcath Systems, Inc. has developed a system, the Delcath system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.”
Insitutional Activity: The institutional sentiment decreased to 1.13 in Q2 2016. Its down 0.30, from 1.43 in 2016Q1. The ratio dived, as 7 funds sold all Delcath Systems, Inc. shares owned while 1 reduced positions. 2 funds bought stakes while 7 increased positions. They now own 1.85 million shares or 18.13% less from 2.26 million shares in 2016Q1.
Deutsche Bancorp Ag accumulated 5 shares or 0% of the stock. Ladenburg Thalmann accumulated 0% or 1,456 shares. Wells Fargo And Co Mn last reported 157 shares in the company. Citadel Advisors Lc holds 0% or 157,333 shares in its portfolio. Barclays Public Limited Company holds 0% or 15 shares in its portfolio. Gru One Trading Lp last reported 5,123 shares in the company. Royal Bank & Trust Of Canada accumulated 2,563 shares or 0% of the stock. Blackrock Institutional Tru Na owns 531,871 shares or 0% of their US portfolio. Moreover, Kcg Hldg has 0% invested in Delcath Systems, Inc. (NASDAQ:DCTH) for 12,403 shares. Moreover, Renaissance Technologies Ltd Limited Liability Company has 0% invested in Delcath Systems, Inc. (NASDAQ:DCTH) for 754,998 shares. Susquehanna Int Grp Llp owns 39,047 shares or 0% of their US portfolio. Goldman Sachs Group has 0% invested in the company for 15,211 shares. The Pennsylvania-based Vanguard has invested 0% in Delcath Systems, Inc. (NASDAQ:DCTH). Geode Cap Limited last reported 0% of its portfolio in the stock. Creative Planning holds 307 shares or 0% of its portfolio.
More notable recent Delcath Systems, Inc. (NASDAQ:DCTH) news were published by: Marketwatch.com which released: “Delcath Systems Inc.” on December 22, 2009, also Prnewswire.com with their article: “Delcath Issues Letter to Stockholders” published on October 18, 2016, Prnewswire.com published: “Review Of Delcath’s CHEMOSAT Accepted For Publication In Advances In Therapy” on October 17, 2016. More interesting news about Delcath Systems, Inc. (NASDAQ:DCTH) were released by: Prnewswire.com and their article: “European Data Supporting Survival Benefit With Delcath’s CHEMOSAT System …” published on July 06, 2016 as well as Prnewswire.com‘s news article titled: “Delcath Announces New U.S. Clinical Sites For FOCUS Phase 3 Trial For Ocular …” with publication date: October 11, 2016.
DCTH Company Profile
Delcath Systems, Inc., incorporated on August 5, 1988, is a late-stage clinical development firm with early commercial activity in Europe focused on cancers of the liver. The Firm is a specialty pharmaceutical and medical device firm developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.